https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/accounts-payable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/accounts-receivable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/accrual-for-taxes-other-than-income-taxes-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/accrued-liabilities-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/accumulated-depreciation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability-1 https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/acquisitions https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/adjustments-noncash-items-to-reconcile-net-income-loss-to-cash-provided-by-used-in-operating-activities-other https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/advertising-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/amortization https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/aoci https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/asset-impairment-charges https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/assets-fair-value-disclosure-nonrecurring https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/assets-noncurrent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/available-for-sale-gross-realized-gain-loss-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/available-for-sale-securities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/basic-shares https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/buyback-authorization https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/buybacks-share-repurchases https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/buybacks-stock-repurchased-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/buybacks-treasury-stock-cost https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/capital-expenditures https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cash-and-equivalents https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cash-divested-from-deconsolidation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cash-flow-breakdown https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/common-stock-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/comprehensive-income https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/construction-in-progress-gross https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/contractual-obligation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/convertible-debt-fair-value-disclosures https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/convertible-long-term-notes-payable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/convertible-notes-payable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/convertible-notes-payable-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cost-method-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cost-of-services https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/current-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/current-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-conversion-converted-instrument-shares-issued https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-conversion-original-debt-amount https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-convertible-effective-interest-rate https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-face-amount https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-increase-accrued-interest https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-issued https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-longterm-and-shortterm-combined-amount https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/debt-repaid https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-revenue https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-inventory https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-net-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-bonuses https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-deferred-rent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-valuation-allowance-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-assets-valuation-allowance-noncurrent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-liabilities-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/deposit-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/depreciation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/diluted-shares https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/discontinued-operation-income-loss-from-discontinued-operation-before-income-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/discontinued-operation-tax-effect-of-discontinued-operation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/due-from-employees-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/due-from-related-parties-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/due-to-related-parties-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/effective-tax-rate https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/eps https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/eps-basic https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/equity-method-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/excise-and-sales-taxes https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/fair-value-inputs-discount-rate https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/financing-cash-flow https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-future-amortization-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/future-amortization-expense-after-year-five https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/future-amortization-expense-year-five https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/future-amortization-expense-year-four https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/future-amortization-expense-year-one https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/future-amortization-expense-year-three https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/future-amortization-expense-year-two https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/gain-loss-on-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/gain-loss-on-investments-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/general-and-administrative-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/goodwill https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/goodwill-acquired https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/goodwill-allocation-adjustment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/goodwill-and-intangible-asset-impairment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/goodwill-impairment-loss https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/goodwill-purchase-accounting-adjustments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/gross-profit https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/impairment-of-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-share https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from-discontinued-operations-net-of-tax-per-diluted-share https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from-equity-method-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from-per-basic-share https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-loss-from-per-diluted-share https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-tax-expense-benefit-discontinued-operations-extraordinary-items https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-tax-holiday-aggregate-dollar-amount https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/income-taxes-paid https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-deferred-income-taxes https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-due-from-related-parties-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-due-to-related-parties-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-other-current-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-other-current-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-other-operating-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-property-and-other-taxes-payable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/incremental-common-shares-attributable-to-conversion-of-debt-securities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/interest-costs-capitalized https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/interest-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/interest-paid https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/interest-payable-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-finished-goods https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-raw-materials https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-work-in-process https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/inventory-write-down https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/investing-cash-flow https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/investment-income-interest https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/investment-interest-rate https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/investment-interest-rate-range-end https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/investment-interest-rate-range-start https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/investments-fair-value-disclosure https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/liabilities-noncurrent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/long-term-debt https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/long-term-debt-fair-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/long-term-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/long-term-loans-payable https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/net-change-in-cash https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/net-income https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/noncash-or-part-noncash-acquisition-noncash-financial-or-equity-instrument-consideration-shares-issued https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/oci-derivatives-qualifying-as-hedges-net-of-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/oci-net-of-tax https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-cash-flow https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-expenses https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-income https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-current-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-current-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-long-term-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-noncurrent-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/paid-in-capital-tax-effect-from-share-based-compensation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-for-mortgage-deposits https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-for-repurchase-of-convertible-preferred-stock https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-to-acquire-longterm-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-to-acquire-short-term-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/payments-to-develop-real-estate-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/prepaid-expense-other-noncurrent https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-bank-debt https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-repayments-of-lines-of-credit https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-sale-of-equity-method-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-sale-of-other-property-plant-and-equipment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-sale-of-short-term-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/property-plant-equipment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/provision-for-doubtful-accounts https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/related-party-transaction-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/repayments-of-bank-debt https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/research-and-development https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/restricted-stock-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/retained-earnings https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/sales-revenue-services-gross https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/sales-revenue-services-net https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/selling-and-marketing-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/shareholders-equity https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/shares-authorized https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/shares-issued https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/shares-repurchased https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/shipping-handling-and-transportation-costs https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/short-term-borrowings https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/short-term-debt https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/short-term-investments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-award-award-vesting-rights-percentage https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-award-number-of-shares-authorized https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-award-plan-modification-incremental-compensation-cost https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-based-compensation https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-option-plan-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-exercisable-remaining-term https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-grants-in-period https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-outstanding-remaining-term https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-options-vested-and-expected-to-vest-outstanding-remaining-term https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stock-repurchase-program-authorized-amount https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/stockholders-equity-other https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-nondeductible-expense-impairment-losses https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-nondeductible-expense-meals-and-entertainment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-nondeductible-expense-other https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-tax-credits-investment https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-tax-exempt-income https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/tax-rate-reconciliation-tax-holidays https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/total-assets https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/total-liabilities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/treasury-stock-acquired-average-cost-per-share https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/unrealized-gain-loss-on-derivatives https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/unrealized-gain-loss-on-securities https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/utb-change https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/utb-decrease-from-settlements https://stock.noler.com/us/stock/wuxi-pharmatech-cayman-inc/utb-reduction-from-statute-lapse